Ajay S. Yekkirala, PhD
Affiliations: | 2007-2011 | Pharmacology | University of Minnesota, Twin Cities, Minneapolis, MN |
| 2011-2018 | Neurobiology | Harvard Medical School - Boston Children's Hospital |
Google:
"Ajay Yekkirala"Mean distance: 13271
Parents
Sign in to add mentor| Philip S. Portoghese | grad student | 2011 | UMN | |
| (Elucidating the role of opioid receptor heteromers as targets for analgesic drug design.) | ||||
| Clifford Woolf | post-doc | 2011-2018 | (Neurotree) | |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Sprague JM, Yekkirala AS, Singh B, et al. (2023) Bortezomib-induced neuropathy is in part mediated by the sensitization of TRPV1 channels. Communications Biology. 6: 1228 |
| Robinson KC, Kemény LV, Fell GL, et al. (2021) Reduced MC4R signaling alters nociceptive thresholds associated with red hair. Science Advances. 7 |
| Talbot S, Doyle B, Huang J, et al. (2020) Vagal sensory neurons drive mucous cell metaplasia. The Journal of Allergy and Clinical Immunology |
| Knezevic NN, Yekkirala A, Yaksh TL. (2017) Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics. Anesthesia and Analgesia. 125: 1714-1732 |
| Yekkirala AS, Roberson DP, Bean BP, et al. (2017) Breaking barriers to novel analgesic drug development. Nature Reviews. Drug Discovery |
| Yekkirala AS, Roberson DP, Bean BP, et al. (2017) Breaking barriers to novel analgesic drug development. Nature Reviews. Drug Discovery |
| Sisignano M, Angioni C, Park CK, et al. (2016) Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathic pain. Proceedings of the National Academy of Sciences of the United States of America |
| Chandran V, Coppola G, Nawabi H, et al. (2016) A Systems-Level Analysis of the Peripheral Nerve Intrinsic Axonal Growth Program. Neuron |
| Le Naour M, Akgün E, Yekkirala A, et al. (2013) Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance. Journal of Medicinal Chemistry. 56: 5505-13 |
| Yekkirala AS, Kalyuzhny AE, Portoghese PS. (2013) An immunocytochemical-derived correlate for evaluating the bridging of heteromeric mu-delta opioid protomers by bivalent ligands. Acs Chemical Biology. 8: 1412-6 |